MODEL VERDICT
Cronos Group Inc. (CRON)
Relative Valuation•Peer multiples, competitive benchmarking & quality-adjusted fair value
The market is pricing Cronos Group Inc. at a 49.2% premium to its peer-implied fair value.
19 industry peers matched by industry sector due to narrow curated coverage
| Ticker | Company | Market Cap | P/E | EV/EBITDA |
|---|---|---|---|---|
| TAK | Takeda Pharmaceutical Company Limited | $48.84B | 39.28x | 9.08x |
| HLN | Haleon plc | $39.9B | 18.73x | 13.45x |
| TEVA | Teva Pharmaceutical Industries Limited | $36.66B | 26.23x | 15.98x |
| ZTS | Zoetis Inc. | $33B | 13.07x | 9.84x |
| VTRS | Viatris Inc. | $17.9B | -5.12x | 231.16x |
| NBIX | Neurocrine Biosciences, Inc. | $15.89B | 33.9x | 24.01x |
| ELAN | Elanco Animal Health Incorporated | $12.1B | -51.53x | 16.7x |
| RDY | Dr. Reddy's Laboratories Limited | $11.06B | 23.22x | 15.63x |
| LNTH | Lantheus Holdings, Inc. | $6.76B | 30.46x | 16.81x |
| AMRX | Amneal Pharmaceuticals, Inc. | $5.1B | 73.68x | - |
| INDV | Indivior Pharmaceuticals Inc | $4.78B | 23.35x | 17.31x |
| SUPN | Supernus Pharmaceuticals, Inc. | $2.56B | -65.26x | 45.12x |
3 valuation metrics · peer-median based
| Multiple | Current | Peer Median | vs Peers | Implied Price |
|---|---|---|---|---|
| Forward P/EPrice paid for next year's expected earnings. | 30.97x | 16.51x | Premium +87.57% | $1.44 |
| EV/EBITDAEnterprise value versus operating cash earnings proxy. | 83.51x | 16.34x | Premium +410.98% | $2.23 |
| P/FCFPrice paid for free cash flow. | 6895.67x | 19.1x | Premium +36005.46% | $0.01 |
How the model derives the final fair value from peer baselines and quality metrics
Premium: The stock is trading at a 97.41% premium to its quality-adjusted fair value of $1.37. The market is pricing the stock 49.34% above our model's estimate.
Quality metrics are broadly comparable to peers.
Quality adjustments are capped at ±15% (up to ±20% for financial services) to prevent runaway premiums. Based on trailing twelve months and multi-year CAGR data where available.
How current multiples rank vs 1 years of the stock’s own history
| Multiple | Current | Historical Median | Percentile | Status |
|---|---|---|---|---|
| P/FCF1 years of data | 6895.67x | 136.9x | 100th | Above historical norm |
Cronos Group Inc. currently trades near the highest valuation levels observed during the last 1 years.
Wall Street target prices — 15 analysts
Model-identified caveats to consider
CRON looks expensive versus peers using L2 rescue peers after thin AI peer data, with relative upside of -49.2%.
Answers to common questions about CRON's relative valuation and our methodology.
Cronos Group Inc.'s fair value of $1.38 is the price at which the stock would trade if valued at the same multiples as its 19-company peer group, adjusted for differences in business quality. At $2.71, the stock trades at a -49.08% premium to fair value. This is a reference point, not a price target.
Peers were grouped by industry classification and market capitalization. The 19 companies shown are the closest comparable names with clean, usable financial data.
Cronos Group Inc. has strengths in 3y revenue growth, fcf margin, and challenges in roic, and a quality score that justifies a 4% premium relative to its peer group. The Quality Adjustment section breaks down each driver.
No. This page provides an automated quantitative comparison of Cronos Group Inc. against its peers. It is not investment advice, a recommendation, or a solicitation. Valuation is only one factor in an investment decision — it does not account for growth catalysts, management quality, regulatory risk, or your personal financial situation.
A 49.08% premium is substantial. Large premiums suggest the market is pricing in significant growth or quality advantages that must be delivered to justify the current price. Review the Risk Factors and Historical Context sections to assess whether the gap is justified.
Valuation data is refreshed weekly based on the latest financial filings, market prices, and analyst estimates. Cronos Group Inc.'s fair value, peer multiples, and quality scores will shift over time as new earnings are reported and stock prices change.
Disclaimer: This page is for informational purposes only and does not constitute financial advice. Fair value estimates are model outputs under stated assumptions and should not be relied upon as the sole basis for any investment decision.